-
Product Insights
Acute Promyelocytic Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Promyelocytic Leukemia - Drugs In Development, 2023’, provides an overview of the Acute Promyelocytic Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Promyelocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Secondary Acute Myeloid Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Acute Myeloid Leukemia - Drugs In Development, 2023’, provides an overview of the Secondary Acute Myeloid Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mast Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Mast Cell Leukemia - Drugs In Development, 2023’, provides an overview of the Mast Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mast Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Product Insights
Acute Myelocytic Leukemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Acute Myelocytic Leukemia Clinical Trials Market Report Overview A total of 4,834 Acute Myelocytic Leukemia clinical trials were conducted as of March 2023. The Acute Myelocytic Leukemia clinical trial report provides a comprehensive understanding of the Acute Myelocytic Leukemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key...
-
Sector Analysis
Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Acute Myeloid Leukemia Market Report Overview The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by the abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. The first approval for cell therapy drugs is anticipated in 2023, which is expected to positively...